E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma  

作　　者：WANG Hua Makoto Satoh CHEN Gui-ping LI De-chuan Hirofumi Hamada Yoichi Arai 

机构地区：[1]Department of Urology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China [2]Department of Urology, Se-en Hospital, Tagajyo, Japan [3]Department of Molecular Medicine, Sapporo Medical University, Sapporo, Japan [4]Division of Urology, Chair of Surgery Tohoku University Graduate School of Medicine, Sendai, Japan

出　　处：《Chinese Medical Journal》2011年第7期1082-1087,共6页中华医学杂志（英文版）

摘　　要：Background Our previous studies have demonstrated potent oncolysis efficacy of the E1A, E1B double-restricted replication-competent oncolytic adenovirus AxdAdB-3 for treatment of bladder cancer. Here, we reported the feasibility and efficacy of AxdAdB-3 alone, or in combination with gemcitabine for treating renal cell carcinoma.Background Our previous studies have demonstrated potent oncolysis efficacy of the E1A, E1B double-restricted replication-competent oncolytic adenovirus AxdAdB-3 for treatment of bladder cancer. Here, we reported the feasibility and efficacy of AxdAdB-3 alone, or in combination with gemcitabine for treating renal cell carcinoma.

关 键 词：ONCOLYSIS ADENOVIRUS GEMCITABINE renal cell carcinoma 

分 类 号：TQ658.34[化学工程—精细化工] Q782[生物学—分子生物学]